SCHEMBL19132170

SCHEMBL19132170

Cc1ccc(S(=O)(=O)Nc2cccc(-c3nnc(-c4ccccc4)o3)c2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 2/20 0.63
PTPN1 P18031 2/20 0.63
PTPN5 P54829 2/20 0.63
TSHR P16473 4/20 0.60
HPGD P15428 3/20 0.60
ALOX15 P16050 1/20 0.60
MAPK1 P28482 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
MAPT P10636 5/20 0.60
LMNA P02545 3/20 0.60
ALDH1A1 P00352 3/20 0.60
HTT P42858 1/20 0.60
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58
CA12 O43570 1/20 0.58
CA9 Q16790 1/20 0.58
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
RXFP1 Q9HBX9 1/20 0.57
MAOA P21397 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1505264 0.90 NPC1 (0.58) PTPN2PTPN1PTPN5TSHRHPGD
SCHEMBL1505501 0.86 TCF4 (0.64) PTPN2PTPN1PTPN5TSHRHPGD
SCHEMBL14877794 0.78 CA12 (0.76) LMNAALDH1A1CA1CA2CA12
SCHEMBL27899314 0.76 NPC1 (0.61) HPGDMAPTLMNAALDH1A1HTT
SCHEMBL28254419 0.76 TYMS (0.55) TSHRHPGDNPSR1MAPTNPC1
SCHEMBL19119164 0.76 CA12 (1.00) HPGDMAPK1MAPTLMNAALDH1A1
SCHEMBL322990 0.76 CA12 (1.00) HPGDMAPK1MAPTLMNAALDH1A1
SCHEMBL14125611 0.76 CA12 (0.63) MAPK1MAPTLMNAALDH1A1HTT
SCHEMBL3701951 0.75 CA12 (0.71) HPGDMAPK1MAPTLMNAALDH1A1
SCHEMBL13167620 0.75 CA12 (0.89) HPGDMAPK1MAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170204073-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2017-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170204073-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE NSUN2, UPF1, NSUN3 PTPN2 3071/4885PTPN1 2992/4885PTPN5 2727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.